Odyssey Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of next-generation precision medicines for inflammatory diseases and cancer. Founded in 2021 and headquartered in Boston, Massachusetts, the company integrates advanced technologies in drug discovery, including high-throughput screening, structural biology, and artificial intelligence, to target complex biological pathways that were previously considered undruggable. Odyssey's platform aims to create a diverse pipeline of small molecules and protein therapeutics that address significant unmet medical needs. The company's strategy involves a multi-disciplinary approach, combining deep expertise in molecular biology with computational chemistry to accelerate the transition from target identification to clinical development. Their research focuses on modulating the immune system and targeting specific drivers of oncogenesis to provide more effective and safer treatments. Led by a team of experienced drug hunters and scientists, including founder and CEO Gary D. Glick, Odyssey Therapeutics has raised substantial capital to support its ambitious portfolio. By leveraging its integrated technology stack and specialized expertise, the company seeks to redefine the standards of care for patients suffering from life-threatening and chronic conditions through the delivery of highly potent and selective therapeutic candidates.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!